Lukas Scheibler - Feb 8, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
CHIEF INNOVATION OFFICER
Signature
/s/ David Watson, attorney-in-fact for Lukas Scheibler
Stock symbol
APLS
Transactions as of
Feb 8, 2022
Transactions value $
-$311,500
Form type
4
Date filed
2/10/2022, 07:32 AM
Previous filing
Feb 1, 2022
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $139K +10K +18.57% $13.85 63.9K Feb 8, 2022 Direct F1
transaction APLS Common Stock Sale -$450K -10K -15.66% $45.00 53.9K Feb 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -10K -11.76% $0.00 75K Feb 8, 2022 Common Stock 10K $13.85 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise from 10B5-1 trading plan.
F2 This represents a stock option grant made on 02/08/2019 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.